Nurix Therapeutics, Inc. (NRIX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Arthur T. Sands
Employees:
103
1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA 94158
(415) 660-5320

We are a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging our extensive expertise in E3 ligases together with our proprietary DNA-encoded libraries, we have built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell.

Data derived from most recent annual or quarterly report
Market Cap 566.828 Million Shares Outstanding44.738 Million Avg 30-day Volume 920.424 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.09
Price to Revenue21.1538 Debt to Equity0.0 EBITDA-136.108 Million
Price to Book Value2.376 Operating Margin-396.1234 Enterprise Value341.182 Million
Current Ratio4.247 EPS Growth-28.727 Quick Ratio4.057
1 Yr BETA 1.3726 52-week High/Low 37.43 / 7.52 Profit Margin-394.2142
Operating Cash Flow Growth-309.2488 Altman Z-Score2.1065 Free Cash Flow to Firm -125.661 Million
Earnings Report2022-07-07
View SEC Filings from NRIX instead.

View recent insider trading info

Funds Holding NRIX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NRIX BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-05-26:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-05-06:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-04-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-03-02:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2022-01-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-10:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-27:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    2.8 Thousand total shares from 4 transactions

    Exercise Derivative Conversion (M)

    77.3 Thousand total shares from 5 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    VAN HOUTE HANS CHIEF FINANCIAL OFFICER

    • Officer
    70,522 2022-05-31 3

    SIEGALL CLAY B

    • Director
    17,500 2022-05-05 1

    GREGORY JULIA P

    • Director
    17,500 2022-05-05 1

    REINSDORF JUDITH A

    • Director
    17,500 2022-05-05 3

    SILVA PAUL M

    • Director
    17,500 2022-05-05 3

    KUNKEL LORI ANNE

    • Director
    17,500 2022-05-05 1

    LACEY DAVID L.

    • Director
    17,500 2022-05-05 1

    WOLFF STEFANI EVP AND COO

    • Officer
    16,024 2022-04-30 3

    HANSEN GWENN CHIEF SCIENTIFIC OFFICER

    • Officer
    83,502 2022-04-30 11

    RING CHRISTINE GENERAL COUNSEL

    • Officer
    36,327 2022-04-30 11

    SANDS ARTHUR T PRESIDENT, CEO

    • Officer
    • Director
    300,000 2022-01-20 1

    BEAURANG PIERRE CHIEF BUSINESS OFFICER

    • Officer
    127,558 2021-08-10 2

    COLUMN GROUP L P

    COLUMN GROUP GP, LP

    COLUMN GROUP II, LP

    COLUMN GROUP II GP, LP

    PONOI CAPITAL, LP

    PONOI MANAGEMENT, LLC

    PONOI II MANAGEMENT, LLC

    PONOI CAPITAL II, LP

    KUTZKEY TIM

    GOEDDEL DAVID V

    • 10% Owner
    • GENERAL PARTNER
    No longer subject to file 2021-05-07 0

    COLUMN GROUP L P

    SVENNILSON PETER

    • 10% Owner
    No longer subject to file 2021-05-07 0

    THIRD ROCK VENTURES III, L.P.

    THIRD ROCK VENTURES GP III, L.P.

    TRV GP III, LLC

    STARR KEVIN P

    TEPPER ROBERT I

    LEVIN MARK J

    • 10% Owner
    3,682,941 2021-05-06 0

    TONG JEFFREY K

    • Director
    • 10% Owner
    17,500 2021-05-06 0

    CHEN LEON

    • Director
    17,500 2021-05-06 0

    REDMILE GROUP, LLC

    GREEN JEREMY

    • 10% Owner
    No longer subject to file 2020-07-28 0

    WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P.

    • 10% Owner
    No longer subject to file 2020-07-28 0

    TJIAN ROBERT

    • Director
    124,999 2020-07-28 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    VAN HOUTE HANS - Officer CHIEF FINANCIAL OFFICER

    2022-06-01 16:57:59 -0400 2022-05-31 M 68,333 d 0 direct

    VAN HOUTE HANS - Officer CHIEF FINANCIAL OFFICER

    2022-06-01 16:57:59 -0400 2022-05-31 M 68,333 $0.84 a 70,522 direct 16.2816 20.462 29.923 5 0.0 1

    SIEGALL CLAY B - Director

    2022-05-06 17:43:06 -0400 2022-05-05 A 17,500 a 17,500 direct

    SILVA PAUL M - Director

    2022-05-06 17:44:38 -0400 2022-05-05 A 17,500 a 17,500 direct

    LACEY DAVID L. - Director

    2022-05-06 17:40:18 -0400 2022-05-05 A 17,500 a 17,500 direct

    REINSDORF JUDITH A - Director

    2022-05-06 17:41:33 -0400 2022-05-05 A 17,500 a 17,500 direct

    KUNKEL LORI ANNE - Director

    2022-05-06 17:23:28 -0400 2022-05-05 A 17,500 a 17,500 direct

    GREGORY JULIA P - Director

    2022-05-06 17:22:28 -0400 2022-05-05 A 17,500 a 17,500 direct

    HANSEN GWENN - Officer CHIEF SCIENTIFIC OFFICER

    2022-05-03 19:05:41 -0400 2022-05-02 S 1,098 $11.75 d 17,151 direct -10.431 -24.1379 -16.1207 1.8103 25 -32.069 17

    VAN HOUTE HANS - Officer CHIEF FINANCIAL OFFICER

    2022-05-03 19:03:47 -0400 2022-05-02 S 697 $11.75 d 2,189 direct -10.431 -24.1379 -16.1207 1.8103 25 -32.069 17

    WOLFF STEFANI - Officer EVP AND COO

    2022-05-03 19:04:41 -0400 2022-05-02 S 330 $11.75 d 632 direct -10.431 -24.1379 -16.1207 1.8103 25 -32.069 17

    RING CHRISTINE - Officer GENERAL COUNSEL

    2022-05-03 19:03:03 -0400 2022-05-02 S 660 $11.75 d 3,403 direct -10.431 -24.1379 -16.1207 1.8103 25 -32.069 17

    HANSEN GWENN - Officer CHIEF SCIENTIFIC OFFICER

    2022-05-03 19:05:41 -0400 2022-04-30 M 3,206 a 18,249 direct -10.431 -24.1379 -16.1207 1.8103 25 -32.069 17

    RING CHRISTINE - Officer GENERAL COUNSEL

    2022-05-03 19:03:03 -0400 2022-04-30 M 1,924 a 4,063 direct -10.431 -24.1379 -16.1207 1.8103 25 -32.069 17

    HANSEN GWENN - Officer CHIEF SCIENTIFIC OFFICER

    2022-05-03 19:05:41 -0400 2022-04-30 M 3,206 d 48,102 direct

    VAN HOUTE HANS - Officer CHIEF FINANCIAL OFFICER

    2022-05-03 19:03:47 -0400 2022-04-30 M 2,886 d 43,291 direct

    VAN HOUTE HANS - Officer CHIEF FINANCIAL OFFICER

    2022-05-03 19:03:47 -0400 2022-04-30 M 2,886 a 2,886 direct -10.431 -24.1379 -16.1207 1.8103 25 -32.069 17

    WOLFF STEFANI - Officer EVP AND COO

    2022-05-03 19:04:41 -0400 2022-04-30 M 962 d 14,430 direct

    WOLFF STEFANI - Officer EVP AND COO

    2022-05-03 19:04:41 -0400 2022-04-30 M 962 a 962 direct -10.431 -24.1379 -16.1207 1.8103 25 -32.069 17

    RING CHRISTINE - Officer GENERAL COUNSEL

    2022-05-03 19:03:03 -0400 2022-04-30 M 1,924 d 28,861 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    NURIX THERAPEUTICS INC NRIX 2022-06-24 22:15:03 UTC 0.9436 0.6264 600000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 21:45:03 UTC 0.9436 0.6264 600000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 21:15:04 UTC 0.9436 0.6264 600000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 20:45:03 UTC 0.949 0.621 600000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 20:15:03 UTC 0.949 0.621 600000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 19:45:03 UTC 0.949 0.621 600000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 19:15:03 UTC 0.949 0.621 600000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 18:45:03 UTC 1.026 0.544 600000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 18:15:04 UTC 1.026 0.544 600000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 17:45:03 UTC 1.026 0.544 600000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 17:15:03 UTC 1.026 0.544 600000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 16:45:03 UTC 0.9716 0.5984 600000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 16:15:03 UTC 0.9716 0.5984 600000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 15:45:03 UTC 0.9716 0.5984 450000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 15:15:03 UTC 0.9716 0.5984 450000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 14:45:03 UTC 0.8437 0.7263 450000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 14:15:03 UTC 0.8437 0.7263 450000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 13:45:03 UTC 0.8437 0.7263 450000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 13:15:03 UTC 0.8437 0.7263 450000
    NURIX THERAPEUTICS INC NRIX 2022-06-24 12:45:03 UTC 0.8437 0.7263 450000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments